TYRA · Tyra Biosciences Inc.
AI read · Neutral
The AI's read
Tyra reported Phase 2 proof of concept and identified a 60 mg dose for registrational studies. A 57% complete response at 60 mg fell short of prior 70%-80% expectations, so positives and negatives balance.